DUBAI, United Arab Emirates-Thursday 18 June 2020 [ AETOS Wire ]
Arzan Wealth (DIFC) Limited (‘Arzan Wealth’), a Dubai-based advisory firm regulated by the Dubai Financial Services Authority, is pleased to announce that it has advised its client on the acquisition of a medical technology campus in Orange County, California, USA.
The HQ office campus, located on 9 acres at Aliso Viejo Parkway in Orange County, California, consists of three newly refurbished buildings comprising 159,746sft, and is fully let to Glaukos Corporation on a triple net basis for remaining term of 12 years with an annual indexation of 3%. The campus houses the headquarters offices of Glaukos as well as their primary R&D facilities.
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos was the first company to introduce Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. Glaukos is a global entity listed in New York Stock Exchange and has a market cap of USD1.7bn (as of Jun 12, 2020).
Arzan Wealth acted as the Sub Strategic Advisor on the structuring and acquisition of the asset and will continue in this role during the holding period of this investment, which is projected to deliver average monthly income to clients equal to 9.15 % per annum.
Muhannad Abulhasan, CEO of Arzan Wealth said:
“We are pleased to be able to advise on this unique opportunity in the health care real estate industry, and in a highly desirable part of Orange County, California. The acquisition of the corporate headquarter and R&D facilities of Glaukos Corporation exemplifies the philosophy of Arzan Wealth, which is based on the pursuit of high quality assets that offer our clients capital protection and a predictable monthly income stream. It is critical that investors focus on reducing risks and pursuing predictable and regular income streams from their portfolios, especially during these uncertain economic times caused by the coronavirus pandemic. As always, our primary objective at Arzan Wealth continues to be the protection of our clients’ wealth and legacies, by reducing risks and diversifying income sources for them and their future generations. We are grateful to our clients for the confidence they continue to place in Arzan Wealth.”
Notes to Editors
About Arzan Wealth (DIFC) Limited
Arzan Wealth is an investment advisory firm registered at the Dubai International Financial Centre (DIFC), and is regulated by the Dubai Financial Services Authority (DFSA). Arzan Wealth currently advises various professional clients on real estate, private equity and other investments with a total value of assets advised around US$ 1.97 Billion. Arzan Wealth focuses on arranging yielding investments in major global markets, as well as bespoke investments that meet the requirements of specific clients.
Past or projected performance is not necessarily a reliable indicator of future results.
Contacts
Ahmad AlSabbrei
Head of Investment Operations
a.alsabbrei@arzanwealth.com
+965 9988 8624
Permalink : https://www.aetoswire.com/news/arzan-wealth-advises-on-acquisition-of-a-medical-technology-campus-in-usa/en
Arzan Wealth (DIFC) Limited (‘Arzan Wealth’), a Dubai-based advisory firm regulated by the Dubai Financial Services Authority, is pleased to announce that it has advised its client on the acquisition of a medical technology campus in Orange County, California, USA.
The HQ office campus, located on 9 acres at Aliso Viejo Parkway in Orange County, California, consists of three newly refurbished buildings comprising 159,746sft, and is fully let to Glaukos Corporation on a triple net basis for remaining term of 12 years with an annual indexation of 3%. The campus houses the headquarters offices of Glaukos as well as their primary R&D facilities.
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos was the first company to introduce Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. Glaukos is a global entity listed in New York Stock Exchange and has a market cap of USD1.7bn (as of Jun 12, 2020).
Arzan Wealth acted as the Sub Strategic Advisor on the structuring and acquisition of the asset and will continue in this role during the holding period of this investment, which is projected to deliver average monthly income to clients equal to 9.15 % per annum.
Muhannad Abulhasan, CEO of Arzan Wealth said:
“We are pleased to be able to advise on this unique opportunity in the health care real estate industry, and in a highly desirable part of Orange County, California. The acquisition of the corporate headquarter and R&D facilities of Glaukos Corporation exemplifies the philosophy of Arzan Wealth, which is based on the pursuit of high quality assets that offer our clients capital protection and a predictable monthly income stream. It is critical that investors focus on reducing risks and pursuing predictable and regular income streams from their portfolios, especially during these uncertain economic times caused by the coronavirus pandemic. As always, our primary objective at Arzan Wealth continues to be the protection of our clients’ wealth and legacies, by reducing risks and diversifying income sources for them and their future generations. We are grateful to our clients for the confidence they continue to place in Arzan Wealth.”
Notes to Editors
About Arzan Wealth (DIFC) Limited
Arzan Wealth is an investment advisory firm registered at the Dubai International Financial Centre (DIFC), and is regulated by the Dubai Financial Services Authority (DFSA). Arzan Wealth currently advises various professional clients on real estate, private equity and other investments with a total value of assets advised around US$ 1.97 Billion. Arzan Wealth focuses on arranging yielding investments in major global markets, as well as bespoke investments that meet the requirements of specific clients.
Past or projected performance is not necessarily a reliable indicator of future results.
Contacts
Ahmad AlSabbrei
Head of Investment Operations
a.alsabbrei@arzanwealth.com
+965 9988 8624
Permalink : https://www.aetoswire.com/news/arzan-wealth-advises-on-acquisition-of-a-medical-technology-campus-in-usa/en